/BCTX
BCTX Stock - BriaCell Therapeutics Corp.
Healthcare|BiotechnologyNASDAQ
$8.95-0.67%
$0.06 (-0.67%) • Dec 19
43
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $9.85
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.86 – $9.04
TARGET (TP)$10.29
STOP LOSS$8.23
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.92
52W High$98.20
52W Low$3.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-147,893 | $-114,643 | $-20,508 | $-19,417 | $-19,462 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-37,733,686 | $-45,544,884 | $-31,256,369 | $-19,440,476 | $-8,899,926.5 |
| Net Income | $-36,495,163 | $-6,547,442 | $-27,267,613 | $-34,126,699 | $-17,626,513 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-86.25 | $-59.69 | $-261.86 | $-330.38 | $-585.01 |
Company Overview
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BCTXBeat Rate
38%
Last 13 quarters
Avg Surprise
-881.7%
EPS vs Estimate
Beats / Misses
5/8
Last 12 quarters
Latest EPS
$-4.35
Q4 2025
EPS Surprise History
Q1 24
-255.0%
$-106.45vs$-29.99
Q2 24
+120.0%
$16.49vs$-82.46
Q3 24
No data
Q4 24
-10893.3%
$-32.98vs$-0.30
Q1 25
-20.1%
$-23.30vs$-19.40
Q2 25
+6.8%
$-16.40vs$-17.60
Q4 25
+13.4%
$-10.49vs$-12.11
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Dec 11, 2025 | — | $-4.35 | — | — |
Q4 2025 | Oct 27, 2025 | $-12.11 | $-10.49 | +13.4% | ✓ BEAT |
Q2 2025 | Jun 16, 2025 | $-17.60 | $-16.40 | +6.8% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-19.40 | $-23.30 | -20.1% | ✗ MISS |
Q4 2024 | Dec 16, 2024 | $-0.30 | $-32.98 | -10893.3% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | — | $-0.73 | — | — |
Q2 2024 | Jun 14, 2024 | $-82.46 | $16.49 | +120.0% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | $-29.99 | $-106.45 | -255.0% | ✗ MISS |
Q4 2023 | Dec 14, 2023 | $-26.99 | $-74.96 | -177.7% | ✗ MISS |
Q3 2023 | Jul 31, 2023 | — | $-1.70 | — | — |
Q2 2023 | Jun 14, 2023 | $-53.97 | $-47.98 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-55.47 | $-115.44 | -108.1% | ✗ MISS |
Q4 2022 | Dec 14, 2022 | $-49.48 | $-10.49 | +78.8% | ✓ BEAT |
Q3 2022 | Jul 5, 2022 | $-0.19 | $-0.43 | -128.5% | ✗ MISS |
Q2 2022 | Jun 13, 2022 | $-28.49 | $-47.98 | -68.4% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-25.49 | $-35.98 | -41.2% | ✗ MISS |
Q4 2021 | Dec 14, 2021 | — | $-22.49 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-2735.77 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-139.43 | — | — |
Latest News
BriaCell Therapeutics Publishes Phase 3 Bria-IMT Clinical Study In Metastatic Breast Cancer
📈 PositiveBenzinga•Dec 18, 2025, 12:34 PM
BriaCell Shares Survival And Biomarker Results For Breast Cancer Therapy At Major San Antonio Conference
📈 PositiveBenzinga•Dec 10, 2025, 12:37 PM
BriaCell Therapeutics Announces Phase 3 Clinical Study Screened Over 230 And Enrolled Over 160 Patients; Topline Data Expected As Early As 1H 2026
📈 PositiveBenzinga•Dec 9, 2025, 12:37 PM
BriaCell Therapeutics To Present Phase 2 Survival, And Phase 3 Biomarker Data Across Three Clinical Posters At 2025 SABCS
📈 PositiveBenzinga•Dec 2, 2025, 12:39 PM
BriaCell Therapeutics shares are trading higher after the company announced that it will highlight Phase 2 safety and efficacy signals and biomarker findings in both the Phase 2 and the pivotal Phase 3 studies at 2025 SABCS.
📈 PositiveBenzinga•Nov 25, 2025, 07:45 PM
BriaCell Therapeutics Says Pivotal Phase 3 Study Of Bria-IMT+CPI Is Ongoing With Interim Analysis Expected In H1-2026
➖ NeutralBenzinga•Nov 25, 2025, 12:39 PM
BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS
📈 PositiveBenzinga•Nov 25, 2025, 12:37 PM
BriaCell Therapeutics' Unit Partners With Research.AI To Design Anti-Cancer Isoform-selective Kinase Inhibitors
📈 PositiveBenzinga•Nov 20, 2025, 12:36 PM
BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium
📈 PositiveBenzinga•Nov 18, 2025, 12:32 PM
BriaCell Therapeutics Presents Evidence Of Strong Immune System Engagement And Anti-Cancer Activity Of Next-Gen Bria-OTS+ Platform In Preclinical Models At SITC Annual Meeting
📈 PositiveBenzinga•Nov 7, 2025, 12:37 PM
BriaCell To Present Preclinical Data On Next-Gen Cancer Vaccine Platform At SITC 2025
📈 PositiveBenzinga•Nov 4, 2025, 12:36 PM
The Independent Data Safety Monitoring Board Has Issued Its Fourth Consecutive Positive Recommendation Following Review Of Safety Data From BriaCell Therapeutics' Phase 3 Study Of Bria-IMT Plus An Immune Checkpoint Inhibitor For Metastatic Breast Cancer
📈 PositiveBenzinga•Oct 22, 2025, 11:36 AM
BriaCell Therapeutics Adds Major Cancer Centers Including Dartmouth Cancer Center, Cedars-Sinai Medical Center, And Winship Cancer Institute Of Emory University, To Its Ongoing Pivotal Phase 3 Cancer Immunotherapy Trial And Expects To Report Top-Line Results In The First Half Of 2026
📈 PositiveBenzinga•Oct 21, 2025, 11:56 AM
BriaCell Therapeutics Collaborates With MSK Cancer Center's Therapeutics Accelerator Cohort Program To Accelerate Clinical Development Of Bria-OTS+ For Multiple Cancer Indications
📈 PositiveBenzinga•Oct 21, 2025, 11:39 AM
BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer
📈 PositiveBenzinga•Oct 20, 2025, 11:33 AM
BriaCell to Present Phase 3 Biomarker Data for Bria-IMT in Metastatic Breast Cancer at ESMO 2025
📈 PositiveBenzinga•Oct 13, 2025, 11:34 AM
BriaCell Therapeutics To Present Preclinical Bria-OTS+ Data At SITC Annual Meeting
➖ NeutralBenzinga•Oct 3, 2025, 11:37 AM
HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Raises Price Target to $40
📈 PositiveBenzinga•Aug 27, 2025, 10:12 AM
BriaCell Therapeutics shares are trading higher after the company announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy in JCI Insight journal.
📈 PositiveBenzinga•Aug 26, 2025, 05:17 PM
BriaCell Publishes Breakthrough Cancer Immunotherapy Research In JCI Insight Journal
📈 PositiveBenzinga•Aug 26, 2025, 11:35 AM
Frequently Asked Questions about BCTX
What is BCTX's current stock price?
BriaCell Therapeutics Corp. (BCTX) is currently trading at $8.95 per share. The stock has moved -0.67% today.
What is the analyst price target for BCTX?
No analyst price targets are currently available for this stock.
What sector is BriaCell Therapeutics Corp. in?
BriaCell Therapeutics Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BCTX's market cap?
BriaCell Therapeutics Corp. has a market capitalization of $0.02 billion, making it a small-cap company.
Does BCTX pay dividends?
No, BriaCell Therapeutics Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLR
Allarity Therapeutics, Inc.
$1.03
Mkt Cap: $0.0B
ASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
HOTH
Hoth Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to BCTX for comparison